DUBLIN--(BUSINESS WIRE)--The "Drug Analysis: Xofigo" drug pipelines has been added to ResearchAndMarkets.com's offering.
Xofigo (radium-223; Bayer) is a radioisotope that kills tumor cells with highly localized short-range alpha irradiation. The drug acts as a calcium mimic and is taken up in the areas of increased bone metabolism, which are associated with bone metastases. Xofigo has a long enough half-life of 11.43 days from synthesis for manufacturing and distribution, but the serum half-life of Xofigo is short, with around 0.5% remaining in the blood after 24 hours.
Product Profiles
List of Figures
Figure 1: Xofigo for prostate cancer - SWOT analysis
Figure 2: Drug assessment summary of Xofigo for prostate cancer
Figure 3: Drug assessment summary of Xofigo for prostate cancer
Figure 4: Xofigo sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
List of Tables
Table 1: Xofigo drug profile
Table 2: Xofigo Phase III data in prostate cancer
Table 3: Xofigo Phase III trials in prostate cancer
Table 4: Xofigo sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/25wr34/2018_xofigo?w=4
